Comparison
Abetal34v Amyloidosis C5679882 vs 17q12 Recurrent Deletion Syndrome C6011081
Clinical comparison between Abetal34v Amyloidosis and 17q12 Recurrent Deletion Syndrome for differential diagnosis and treatment planning.
Abetal34v Amyloidosis C5679882
Hereditary amyloidosis with APP gene mutation. Inherited condition. Can increase risk of stroke. Requires genetic testing for diagnosis.
17q12 Recurrent Deletion Syndrome C6011081
A genetic condition from deletion on chromosome 17. Can involve developmental delays, neurological features, and potential kidney involvement. Management requires regular monitoring and supportive therapies.
6 comparison axes
Onset
Abetal34v Amyloidosis C5679882
50-70
17q12 Recurrent Deletion Syndrome C6011081
0-null
Onset patterns differ
Severity
Abetal34v Amyloidosis C5679882
severe
17q12 Recurrent Deletion Syndrome C6011081
moderate
Different severity levels
Chronic
Abetal34v Amyloidosis C5679882
Chronic
17q12 Recurrent Deletion Syndrome C6011081
Chronic
Differing course
Communicable
Abetal34v Amyloidosis C5679882
No
17q12 Recurrent Deletion Syndrome C6011081
No
Different transmission
Body System
Abetal34v Amyloidosis C5679882
neurologic
17q12 Recurrent Deletion Syndrome C6011081
congenital
Same/different system
Category
Abetal34v Amyloidosis C5679882
rare-disease
17q12 Recurrent Deletion Syndrome C6011081
genetic
Different category
Bottom line
abetal34v-amyloidosis-C5679882 and 17q12-recurrent-deletion-syndrome-C6011081 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | Abetal34v Amyloidosis C5679882 | 17q12 Recurrent Deletion Syndrome C6011081 | Discriminating power |
|---|---|---|---|
| Age at recognition | Reported onset is typically middle to later adulthood, about ages 50–70. | Features may be present from birth or early childhood. | High |
| Main clinical pattern | Neurologic hereditary amyloidosis; stroke risk is described, but symptoms are not fully established. | Congenital syndrome with possible developmental delay, neurologic features, and kidney involvement. | Moderate |
| Inheritance clue | Described as an inherited APP gene mutation requiring genetic confirmation. | Caused by a recurrent deletion on chromosome 17; inheritance pattern is not established here. | High |
When to favor each condition
Choose Abetal34v Amyloidosis C5679882 when
Adult-onset neurologic disease with suspected hereditary amyloidosis
The supplied profile emphasizes APP-related amyloidosis and later onset.
Moderate
Family history suggesting an APP mutation
Targeted genetic testing is stated as necessary for diagnosis.
Moderate
Concern about increased stroke risk in an adult
Stroke risk is mentioned, but this finding alone does not establish the diagnosis.
Low
Choose 17q12 Recurrent Deletion Syndrome C6011081 when
Congenital or early developmental presentation
The syndrome is classified as congenital and may begin in infancy.
High
Developmental delay with possible kidney involvement
Both features are described for 17q12 deletion syndrome.
Moderate
Suspected chromosomal deletion rather than APP mutation
The stated etiology is a recurrent chromosome 17q12 deletion.
High
How key tests differ
| Test | Abetal34v Amyloidosis C5679882 | 17q12 Recurrent Deletion Syndrome C6011081 | Interpretation |
|---|---|---|---|
| Genetic testing | APP gene mutation testing is described as required. | Chromosomal testing may identify a 17q12 deletion. | Different genetic targets; a result must be interpreted by a clinician or genetics specialist. |
| Neurologic evaluation | May assess adult neurologic disease and reported stroke risk. | May assess developmental and neurologic features from early life. | Findings support evaluation but do not by themselves confirm either condition. |
| Kidney assessment | Kidney involvement is not established in the supplied data. | Monitoring for possible kidney involvement is described. | Abnormal kidney results require clinical correlation and do not diagnose the syndrome alone. |
Prognosis comparison
Abetal34v Amyloidosis C5679882
- Outcome
- Described as severe and chronic, but individual outcome is not established.
- Factors
- Adult onset, neurologic involvement, and reported stroke risk may influence care.
17q12 Recurrent Deletion Syndrome C6011081
- Outcome
- Described as moderate and chronic, with variable supportive needs.
- Factors
- Developmental, neurologic, and possible kidney features may affect outcome.
Time frame: Long-term; exact survival or progression data are not supplied.
Genetic confirmation, organ involvement, and access to supportive care are relevant.
Complications comparison
| Complication | Presentation |
|---|---|
| Stroke | Increased stroke risk is reported. Stroke risk is not established in the supplied description. Any stroke symptom needs urgent clinical assessment. |
| Developmental impairment | Not described as a congenital developmental disorder. Developmental delay may occur. Severity and functional impact vary and are not quantified here. |
| Kidney disease | Not established from the supplied evidence. Potential kidney involvement warrants monitoring. No specific laboratory cutoff is provided. |
Patient education highlights
- HighDifferent conditions
These are distinct genetic conditions with different typical ages and clinical patterns.
- HighTesting
Diagnosis depends on appropriate genetic testing and clinician interpretation, not symptoms alone.
- MediumMonitoring
Follow-up may address neurologic concerns; kidney monitoring is particularly relevant to 17q12 deletion.